



Suite 6, Level 3
320 Adelaide Street
Brisbane, Qld, 4000
Phone (07) 3229 5755
Fax (07) 3229 4655
ABN 58 008 130 336

20 September 2010

The Manager
Company Announcements
Australian Securities Exchange
Level 4, 20 Bridge Street
Sydney NSW 2000

BioProspect secures alternative Conifer Green Needle Complex supply

Highlights

- Terms Sheet signed for supply of Conifer Green Needle Complex (CGNC), used in BioProspect products *GI-Guard*[™] Oral Paste and *AGRIPRO*[™] Topical Gel
- Alternative source verified by Australian laboratory, found comparable to previous product supplied by Solagran and at more competitive price
- BioProspect to undertake efficacy study on *GI-Guard*[™] Oral Paste with horses, targeting product registration with APVMA (Australian Pesticides & Veterinary Medicines Authority)

Fast-tracking its natural animal health products, Australian natural products provider BioProspect Limited (ASX:BPO) announced today the signing of a Terms Sheet with an alternative supplier of Conifer Green Needle Complex (CGNC), referred to in the Development Agreement with Solagran as “Bioeffective A”.

The CGNC from this alternative source has been tested and verified by a laboratory in Australia and found to be chemically comparable to the product previously supplied by Solagran.

BioProspect’s Managing Director Charles Pellegrino said the Company was pleased with the new agreement, which offered certainty of supply along with superior pricing for the rollout of the Company’s planned horse treatments.

“BioProspect has been seeking to identify alternative supply sources of CGNC, and after extensive market research is very pleased to have secured this agreement,” Mr Pellegrino said.

“The new supplier’s superior pricing bodes well for the launch of equine product *GI-Guard*[™] Oral Paste, and will ensure competitive pricing against the synthetic products used to treat Equine Gastric Ulcer Syndrome (EGUS).”

One of the horse industry’s most common complaints, studies have shown EGUS can be present in 25 to 50 per cent of foals and 60 to 90 per cent of adult horses, depending on age, performance, and evaluated populations. EGUS causes poor performance and particularly affects horses used in competitive activities such as dressage, racing and show jumping.

BioProspect has also committed to an efficacy study with *GI-Guard*[™] Oral Paste in horses to be undertaken by SCEC Pty Ltd, a specialist contract research organisation operated by Dr Sally Colgan.

SCEC conducted the recent successful horse safety study with *GI-Guard*[™] Oral Paste. The new efficacy study will specifically target EGUS and will involve gastroscopic examinations to assess the effectiveness of the product.

Meanwhile, an application for registration of *GI-Guard*[™] Oral Paste has already been submitted to the APVMA, comprising Part 2 (Product Chemistry). The efficacy study will enable Part 8 Efficacy & Safety to be submitted to complete the APVMA application.

BioProspect is also pleased to advise that the new supplier of CGNC is able to provide other products previously supplied by Solagran under the Development Agreement currently subject to legal dispute, as well as certain highly refined pine needle extract products not previously included in this Agreement.

BioProspect has engaged an experienced market research firm to assess the potential of those other products in both areas of animal and human health.

“BioProspect is determined to push ahead with its new animal health products, targeting the global \$15 billion market with an initial focus on the horse industry,” Mr Pellegrino said.

“The Company continues to commercialise its attractive range of natural products, also including the *REGEN*[™] range of natural therapeutic and skin care products (as seen recently on the Nine Network’s *A Current Affair*) and natural termite solution *TERMILONE*[®]. We are determined to deliver shareholder value from this expanding, environmentally friendly product range.”

Yours sincerely



Colin Johnston
Company Secretary